Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs rises on report of favourable US court ruling on top drug

** Shares of Divi's Laboratories  DIVI.NS  gain ~4% at 4,895
rupees 
    ** DIVI top pct gainer on Nifty 50  .NSEI  and Nifty pharma
index  .NIPHARM 
    ** U.S. appeals court puts stay order on US FDA's approval
for generic version of Novartis'  NOVN.S  top-selling heart
failure drug Entresto, for which DIVI makes the API Sacubitril,
Bloomberg Law reports
    ** Novartis did not immediately respond to Reuters' request
for comment
    ** "While litigation is still ongoing, the stay on approval
blocks the launch of generic version of Entresto for now, which
is a positive for DIVI," said Shrikant Akolkar of Nuvama
Institutional Equities
    ** DIVI fell the most in nearly 16 months on Aug. 14 when
Novartis lost initial bid to block generic versions of Entresto
    ** Stock up ~26% YTD vs ~34% gains in pharma index 
    

 (Reporting by Kashish Tandon in Bengaluru)
 ((kashish.tandon@thomsonreuters.com))

Recent news on Divi's Laboratories

See all news